BioCentury | May 20, 2020
Deals

Roche deal, AACR data unveil Vividion’s targeted degradation strategy

With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective targeted protein degraders by using its covalent chemistry to engage untapped ubiquitin ligases. Targeted protein degraders typically connect one...
BioCentury | Jun 28, 2018
Translation in Brief

Synchronous signaling

...them significantly more efficient in their job.” Elizabeth S. Eaton, Staff Writer University of Cambridge CD19 CD3zeta (CD3z) (CD247) CD69 FK506 binding protein 5 (FKBP5) Interleukin-2...
BioCentury | May 9, 2018
Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...
BioCentury | Mar 26, 2018
Preclinical News

Bradner, Gray explore targeted degradation-based model systems

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray published a paper in Nature Chemical Biology demonstrating a generalizable target-specific protein degradation system that can be used to create preclinical models that offer better control...
BioCentury | Mar 26, 2018
Translation in Brief

Tagging out

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over...
BioCentury | Aug 28, 2017
Clinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

...including prostate-specific antigen ( PSA ; KLK3), transmembrane protease serine 2 (TMPRSS2) and FK506 binding protein 5 ( FKBP5...
BioCentury | Aug 23, 2017
Preclinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

...genes, including prostate-specific antigen ( PSA ; KLK3), transmembrane protease serine 2 (TMPRSS2) and FK506 binding protein 5 (FKBP5...
BioCentury | Apr 7, 2017
Targets & Mechanisms

Mastering mTOR

The master regulator mTOR has made its mark as the target of dozens of drugs and clinical candidates for diseases ranging from cancer to diabetes, but David Sabatini thinks its full therapeutic value won’t be...
BioCentury | Mar 29, 2017
Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies suggest topical tacrolimus could help treat lymphedema. In a mouse tail model of lymphedema, a topical formulation of tacrolimus decreased tail swelling and volume, soft tissue thickness, infiltration of inflammatory cells...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
Items per page:
1 - 10 of 275